CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
← catalyst calendarNCT06959121 · readout ≤ 253 d
Sponsored by Pulse Biosciences, Inc. (industry) · PLSE — their whole pipeline →. With Avania.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
135estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-23 | actual | When the study began enrolling |
| Primary completion | Apr 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Atrial Fibrillation
- Maze Procedure
- AF
- Ablation
Intervention
- Device: CellFX® nsPFA™ Cardiac Surgery System
Primary outcomes
what the primary-completion date above is the date OFFreedom from atrial fibrillation/atrial flutter/atrial tachycardia
measured 3-months through 6 months post-index procedure
Incidence of Treatment-Emergent Adverse Events
measured Within 30 days post-concomitant surgical procedure
Permalink · PLSE's whole pipeline · Catalyst calendar · Every registered study · What changed